One of most common mistakes that marketers make during a recession is to focus on cost rather than outcomes.
PRESIDENT AND CEO | PUROHIT NAVIGATION
One of most common mistakes that marketers make during a recession is to focus on cost rather than outcomes. For example, a comprehensive e-learning program may seem expensive initially, but over time it may deliver a greater return on investment, such as behavior conversion, long term loyalty, and heightened product awareness. Selecting tactics that provide amortized value is more effective than short term, less expensive tactics. Initiating a pharmacoeconomic study, say, can lead to various benefits that can be applied in more than one promotion, such as incorporating pivotal data into sales aids, communicating to managed care groups, and demonstrating value to physicians and patients.
Ahnal Purohit
The FDA's move of "acting in the best interest of consumers" may actually open a Pandora's box. It could allow a rise in advertising from online pharmacies, counterfeit drugs, and alternative therapies—all of which are easily available online and are not as strictly regulated as the pharmaceutical industry.
It will be some time before the FDA issues greater clarification on how to best approach online marketing. In the meantime, marketers do have choices. The first is to redesign their banner ads to include information, such as the generic name and fair balance, in a larger pixel-size format (good luck!). The larger format will incur additional costs for companies, so a closer analysis of the return on investment will need to be made.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 18th 2025Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in multiple myeloma and solid tumor bone metastases.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 18th 2025Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in multiple myeloma and solid tumor bone metastases.
2 Commerce Drive
Cranbury, NJ 08512